In total, 42% of those patients showed a putative resistance mechanism to adagrasib, including secondary mutations or amplifications to KRAS; the activation of the RTK–RAS signaling pathway; and the histological transformation of adenocarcinoma to squamous cell carcinoma. The gene discussed is KRAS; the disease is adenocarcinoma.